According to the new research report published by Precedence Research, titled “CAR T-Cell Therapy Market (By Drug Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others; By Indication: Lymphoma, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Others; By End User: Hospitals, Cancer Treatment Centers) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032 (By Product: Traditional, Advanced; By Application: Pottery, Tiles, Abrasives, Sanitary wave, Bricks & pipes, Others; By End User: Medical, Industrial, Building & Construction, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032”, the global CAR T-cell therapy market size is expected to be worth around US$ 6.43 billion by 2032 and is poised to record a yearly growth rate of 11.37% from 2023 to 2032. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on CAR T-cell therapy market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall CAR T-cell therapy market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2032. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2545
The study also provides important advancements in organic and inorganic growth strategies in the worldwide CAR T-cell therapy market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of CAR T-cell therapy market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
CAR T-Cell Therapy Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 2.44 Billion |
| Market Size by 2032 | USD 6.43 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 11.37% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Type, By Indication and By End User |
Also read: Newborn Eye Imaging Systems Market Size to Worth US$ 390.74 Billion By 2032
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the CAR T-cell therapy market.
Some of the prominent players in the CAR T-cell therapy market include
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- MEDIPOST
- PHARMICELL Co., Ltd.
- ANTEROGEN. CO., LTD
- Bristol-Myers Squibb Company
- Novartis AG
- Gilead Sciences, Inc.
- Curocell, Inc.
- JW Therapeutics (Shanghai) Co., Ltd.
- Stempeutics Research PVT LTD
CAR T-Cell Therapy Market Segmentations
By Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma (MM)
- Others
By End User
- Hospitals
- Cancer Treatment Centers
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Report Objectives
- To define, segment, and project the global market size for CAR T-cell therapy market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyse the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyse their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyse the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on CAR T-Cell Therapy Market
5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global CAR T-Cell Therapy Market, By Drug Type
8.1. CAR T-Cell Therapy Market, by Drug Type, 2022-2032
8.1.1 Axicabtagene Ciloleucel
8.1.1.1. Market Revenue and Forecast (2022-2032)
8.1.2. Tisagenlecleucel
8.1.2.1. Market Revenue and Forecast (2022-2032)
8.1.3. Brexucabtagene Autoleucel
8.1.3.1. Market Revenue and Forecast (2022-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2022-2032)
Chapter 9. Global CAR T-Cell Therapy Market, By Indication
9.1. CAR T-Cell Therapy Market, by Indication, 2022-2032
9.1.1. Lymphoma
9.1.1.1. Market Revenue and Forecast (2022-2032)
9.1.2. Acute Lymphocytic Leukemia
9.1.2.1. Market Revenue and Forecast (2022-2032)
9.1.3. Chronic Lymphocytic Leukemia (CLL)
9.1.3.1. Market Revenue and Forecast (2022-2032)
9.1.4. Multiple Myeloma (MM)
9.1.4.1. Market Revenue and Forecast (2022-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2022-2032)
Chapter 10. Global CAR T-Cell Therapy Market, By End User
10.1. CAR T-Cell Therapy Market, by End User, 2022-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2022-2032)
10.1.2. Cancer Treatment Centers
10.1.2.1. Market Revenue and Forecast (2022-2032)
Chapter 11. Global CAR T-Cell Therapy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.1.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.3. Market Revenue and Forecast, by End User (2022-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.1.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.1.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.3. Market Revenue and Forecast, by End User (2022-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.6.3. Market Revenue and Forecast, by End User (2022-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.7.3. Market Revenue and Forecast, by End User (2022-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.3. Market Revenue and Forecast, by End User (2022-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.6.3. Market Revenue and Forecast, by End User (2022-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.7.3. Market Revenue and Forecast, by End User (2022-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.6.3. Market Revenue and Forecast, by End User (2022-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.7.3. Market Revenue and Forecast, by End User (2022-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.5.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.5.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.5.3. Market Revenue and Forecast, by End User (2022-2032)
Chapter 12. Company Profiles
12.1. Kolon TissueGene, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. JCR Pharmaceuticals Co., Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Kolon TissueGene, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. JCR Pharmaceuticals Co., Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. MEDIPOST
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. PHARMICELL Co., Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. ANTEROGEN. CO., LTD
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novartis AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gilead Sciences, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global CAR T-cell therapy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for CAR T-cell therapy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
